pmid	doi	year	title	Hugo_Symbol
29922424	10.22038/IJBMS.2018.26778.6557	2022	Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes.	CD22
33461955	10.1016/j.clml.2020.12.008	2022	Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.	CD22
33602684	10.1158/1078-0432.CCR-20-2399	2022	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.	CD22
33627493	10.1158/1078-0432.CCR-20-3863	2022	CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.	CD22
33640284	10.1016/j.clml.2021.01.014	2022	Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.	CD22
33722856	10.1158/1535-7163.MCT-20-0035	2022	Calicheamicin Antibody-Drug Conjugates with Improved Properties.	CD22
33740268	10.1002/cncr.33469	2022	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.	CD22
33839735	10.1038/s41408-021-00465-9	2022	A novel full-human CD22-CAR T cell therapy with potent activity against CD22<sup>low</sup> B-ALL.	CD22
33887152	10.1089/cbr.2020.4653	2022	<sup>227</sup>Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.	CD22
34088894	10.1038/s41408-021-00499-z	2022	Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.	CD22
34097135	10.1007/s11864-021-00859-8	2022	Current Status of CAR T Cell Therapy for Leukemias.	CD22
34160005	10.1093/ajcp/aqab057	2022	LILRB1: A Novel Diagnostic B-Cell Marker to Distinguish Neoplastic B Lymphoblasts From Hematogones.	CD22
34239307	10.2147/OTT.S312904	2022	Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.	CD22
34290048	10.1158/2326-6066.CIR-20-0675	2022	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.	CD22
34407735	10.1080/10428194.2021.1966780	2022	A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.	CD22
34425260	10.1016/j.jtct.2021.08.012	2022	CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.	CD22
34521107	10.1182/bloodadvances.2021004557	2022	Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.	CD22
34590432	10.1111/1759-7714.14155	2022	Primary mediastinal large B cell lymphoma.	CD22
34625226	10.1016/j.beha.2021.101277	2022	New targets for CAR T therapy in hematologic malignancies.	CD22
34625231	10.1016/j.beha.2021.101305	2022	Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.	CD22
34667217	10.1038/s41598-021-00227-4	2022	Upregulation of CD22 by Chidamide promotes CAR T cells functionality.	CD22
34686527	10.1158/2159-8290.CD-RW2021-150	2022	Dual CD19/CD22 CAR T Cells Show Feasibility in Pediatric/Young Adult B-ALL.	CD22
34691067	10.3389/fimmu.2021.751754	2022	Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.	CD22
34710243	10.1002/ajh.26390	2022	Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.	CD22
34840026	10.1016/j.ejca.2021.10.016	2022	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.	CD22
34882493	10.1200/JCO.20.03585	2022	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.	CD22
34920453	10.1182/bloodadvances.2021006035	2022	Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy.	CD22
34922844	10.1016/j.clml.2021.11.010	2022	The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.	CD22
34973016	10.1007/978-3-030-78775-2_14	2022	Adiponectin and Its Effects on Acute Leukemia Cells: An Experimental and Bioinformatics Approach.	CD22
35007127	10.1200/JCO.21.01693	2022	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.	CD22
35013921	10.1007/s12029-021-00790-z	2022	Spindle Variant Primary Diffuse Large B Cell Lymphoma of the Colon: Case Report and Literature Review.	CD22
35015683	10.1158/2643-3230.BCD-21-0087	2022	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.	CD22
35015686	10.1158/2643-3230.BCD-21-0200	2022	Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies.	CD22
35042232	10.1182/bloodadvances.2021005978	2022	Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab.	CD22
35051588	10.1016/j.trim.2022.101538	2022	Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia.	CD22
35092855	10.1016/j.nano.2022.102523	2022	Overcoming the blood-brain barrier by using a multistage exosome delivery system to inhibit central nervous system lymphoma.	CD22
35121370	10.1016/j.ejca.2021.12.029	2022	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.	CD22
35198451	10.3389/fonc.2022.834288	2022	Prognostic Value of Radiomic Features of <sup>18</sup>F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.	CD22
35222407	10.3389/fimmu.2022.825364	2022	Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.	CD22
35253074	10.1186/s43046-022-00107-6	2022	Simple headache revealed a rare lymphoma: Waldenstrom macroglobulinemia with unique markers: a case report and review of the literature.	CD22
35288466	10.1136/jitc-2021-003882	2022	A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.	CD22
35293685	10.1002/pbc.29664	2022	Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia.	CD22
35399106	10.1038/s41392-022-00924-0	2022	Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.	CD22
35405786	10.3760/cma.j.issn.0253-2727.2022.03.013	2022	[Sequential infusion of anti-CD22 and anti-CD19 CAR-T cells in the treatment of relapsed / refractory childhood acute B lymphoblastic leukemia: two cases report].	CD22
35419923	10.1111/ijlh.13850	2022	Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.	CD22
35421218	10.1182/blood.2021014840	2022	CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.	CD22
35422632	10.2147/OTT.S352760	2022	CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report.	CD22
35442136	10.1080/10428194.2022.2062346	2022	CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor α-chain (CD25) expression and poor prognosis.	CD22
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	CD22
35468945	10.1038/s41375-022-01576-3	2022	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.	CD22
35486592	10.1080/08830185.2022.2067154	2022	Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies.	CD22
35534047	10.1136/jitc-2021-004483	2022	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation.	CD22
35572515	10.3389/fimmu.2022.873789	2022	T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.	CD22
35574341	10.3389/fonc.2022.817969	2022	Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report.	CD22
35605184	10.1182/blood.2022015795	2022	CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.	CD22
35622074	10.1080/16078454.2022.2074704	2022	Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.	CD22
35643855	10.1016/j.clml.2022.04.022	2022	Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.	CD22
35653589	10.1080/14712598.2022.2086043	2022	Bispecific CAR T-cells for B-cell Malignancies.	CD22
35663281	10.1016/j.lrr.2022.100325	2022	Immunotherapy in indolent Non-Hodgkin's Lymphoma.	CD22
35669773	10.3389/fimmu.2022.879983	2022	Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.	CD22
35673721	10.3760/cma.j.cn112151-20211117-00836	2022	[ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases].	CD22
35727422	10.1007/s10815-022-02548-3	2022	Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents.	CD22
35779772	10.1016/j.actbio.2022.06.033	2022	Polysialylated nanoinducer for precisely enhancing apoptosis and anti-tumor immune response in B-cell lymphoma.	CD22
35787551	10.1097/MOH.0000000000000723	2022	Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.	CD22
35979928	10.1177/09636897221117532	2022	A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia.	CD22
36059496	10.3389/fimmu.2022.965224	2022	Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.	CD22
36059523	10.3389/fimmu.2022.969660	2022	Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.	CD22
36093513	10.21037/tcr-22-174	2022	Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt's lymphoma: a case report.	CD22
23264893	10.4161/onci.21815	2021	Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma.	CD22
31585889	10.2741/4806	2021	Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>.	CD22
31900459	10.1038/s41423-019-0355-5	2021	Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment.	CD22
32005917	10.1038/s41409-020-0807-7	2021	CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations.	CD22
32032771	10.1016/j.pep.2020.105594	2021	Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment.	CD22
32245502	10.1186/s13045-020-00856-8	2021	Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.	CD22
32281503	10.1080/10428194.2020.1742902	2021	Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.	CD22
32286905	10.1200/JCO.19.03279	2021	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.	CD22
32291234	10.1016/j.clml.2020.03.004	2021	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.	CD22
32345625	10.1136/jitc-2019-000364	2021	CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.	CD22
32424837	10.1111/bjh.16732	2021	Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.	CD22
32436925	10.1039/d0nr02133d	2021	Identification of a moderate affinity CD22 binding peptide and in vitro optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies.	CD22
32459397	10.1111/jcmm.15425	2021	Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC.	CD22
32495161	10.1007/s11523-020-00729-7	2021	Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas.	CD22
32497402	10.1002/cyto.b.21887	2021	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.	CD22
32503572	10.1186/s13045-020-00905-2	2021	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.	CD22
32589304	10.1634/theoncologist.2020-0560	2021	CD19/CD22 Dual-Targeted CAR-T Therapy Active in Relapsed/Refractory DLBCL.	CD22
32592176	10.1002/eji.202048636	2021	Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy.	CD22
32648276	10.1111/bjh.16949	2021	Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.	CD22
32694050	10.1016/j.clml.2020.06.011	2021	Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia.	CD22
32788237	10.1136/jitc-2020-000896	2021	Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.	CD22
32812370	10.1111/cts.12841	2021	Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.	CD22
32951102	10.1007/s12185-020-03006-5	2021	Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.	CD22
32988266	10.1080/10428194.2020.1827247	2021	Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.	CD22
33067614	10.1182/blood.2020007848	2021	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).	CD22
33077713	10.1038/s41408-020-00371-6	2021	A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.	CD22
33098744	10.1002/pbc.28718	2021	Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.	CD22
33231879	10.1002/cncr.33321	2021	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.	CD22
33256899	10.1053/j.seminhematol.2020.08.001	2021	Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020.	CD22
33259039	10.1007/s11684-020-0808-3	2021	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.	CD22
33273056	10.1158/1535-7163.MCT-20-0046	2021	An Anti-CD22-<i>seco</i>-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models.	CD22
33279178	10.1016/j.beha.2020.101226	2021	Monoclonal antibodies in frontline acute lymphoblastic leukemia.	CD22
33279181	10.1016/j.beha.2020.101225	2021	Antibody based therapy in relapsed acute lymphoblastic leukemia.	CD22
33314603	10.1002/anie.202005934	2021	Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.	CD22
33327999		2021	[Clinical characteristics and prognostic analysis of pediatric pro-B cell acute lymphoblastic leukemia].	CD22
33457105	10.1080/2162402X.2020.1825177	2021	Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting.	CD22
33512414	10.1182/blood.2020009432	2021	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.	CD22
33529389	10.1111/bjh.17333	2021	Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.	CD22
33647817	10.1016/j.cancergen.2021.02.006	2021	Expression of a novel type of KMT2A/EPS15 fusion transcript in FLT3 mutation-positive B-lymphoblastic leukemia with t(1;11)(p32;q23).	CD22
33670075	10.3390/ijms22042150	2021	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.	CD22
33704192	10.3390/curroncol28010027	2021	Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?	CD22
33715150	10.1111/bjh.17382	2021	Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.	CD22
33725422	10.1002/ajh.26160	2021	Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.	CD22
33734005	10.1080/10428194.2021.1894641	2021	Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.	CD22
33762438	10.1126/scitranslmed.abc6401	2021	Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.	CD22
33764809	10.1200/JCO.20.02262	2021	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.	CD22
33807678	10.3390/jof7030186	2021	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.	CD22
33812446	10.19746/j.cnki.issn.1009-2137.2021.02.055	2021	[Research Advances in the Treatment of B-Cell Acute Lymphoblastic Leukemia Based on Surface Antigen Expression --Review].	CD22
33834463	10.3760/cma.j.cn511374-20200416-00273	2021	[Identification of TCF3-ZNF384 fusion by transcriptome sequencing in B cell acute lymphoblastic leukemia and its laboratory and clinical characteristics].	CD22
33858045	10.3760/cma.j.issn.0253-2727.2021.02.009	2021	[In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].	CD22
33869619	10.12998/wjcc.v9.i10.2394	2021	Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report.	CD22
33888899	10.1038/s41591-021-01326-5	2021	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.	CD22
33935029	10.5045/br.2021.2020320	2021	Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas.	CD22
33979977	10.3760/cma.j.issn.0253-2727.2021.04.009	2021	[CART therapy followed by allo-HSCT for patients with B-cell acute lymphoblastic leukemia relapsing after the first hematopoietic stem cell transplantation].	CD22
34102636	10.1159/000516593	2021	Durable Molecular Remission in an Elderly Patient Affected by Relapsed Ph&amp;apos;+ Acute Lymphoblastic Leukemia with T315I and Concomitant p190 and p210 Expression Achieved by Inotuzumab and Ponatinib.	CD22
34106613	10.1097/MD.0000000000025786	2021	Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.	CD22
34133196	10.1200/JCO.21.00377	2021	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.	CD22
34172894	10.1038/s41375-021-01277-3	2021	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.	CD22
34218580	10.3760/cma.j.issn.0253-2727.2021.05.006	2021	[Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].	CD22
34262884	10.2147/ITT.S288546	2021	Targeting CD22 for the Treatment of B-Cell Malignancies.	CD22
34277400	10.3389/fonc.2021.640166	2021	Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL.	CD22
34312556	10.1038/s41591-021-01436-0	2021	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.	CD22
34331563	10.1007/s00277-021-04601-0	2021	Loss of CD22 expression and expansion of a CD22<sup>dim</sup> subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.	CD22
34364920	10.1016/j.jconrel.2021.08.001	2021	Polymeric nanomedicines targeting hematological malignancies.	CD22
34423769	10.5414/CP203907	2021	An open-label, multiple-dose study to assess the preliminary pharmacokinetics, pharmacodynamics, clinical activity, and safety of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in patients with rheumatoid arthritis.	CD22
34521106	10.1182/bloodadvances.2021004716	2021	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.	CD22
34638774	10.3390/ijms221910433	2021	Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.	CD22
34642489	10.1038/s41591-021-01497-1	2021	CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.	CD22
34660330	10.3389/fonc.2021.778039	2021	Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL.	CD22
34691036	10.3389/fimmu.2021.728962	2021	CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.	CD22
34706776	10.1186/s13256-021-03128-2	2021	Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report.	CD22
34765437	10.1016/j.lrr.2021.100275	2021	Role of antibody-based therapy in indolent non-Hodgkin's lymphoma.	CD22
34768899	10.3390/ijms222111470	2021	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.	CD22
34930453	10.1186/s40364-021-00343-3	2021	Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.	CD22
27872741	10.4084/MJHID.2016.061	2020	Novel Drugs in Follicular Lymphoma.	CD22
27957358	10.1155/2016/3598547	2020	Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma.	CD22
28582973	10.1186/s13568-017-0410-5	2020	A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.	CD22
28959500	10.1080/21556660.2017.1315336	2020	Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.	CD22
28976934	10.3390/biomedicines5040059	2020	Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins.	CD22
30089946	10.4103/JOC.JOC_42_18	2020	Contribution of Immunocytochemistry to the Diagnosis of Usual and Unusual Lymphoma Cases.	CD22
30120894	10.1002/hep.30222	2020	Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).	CD22
30575311	10.1002/cam4.1918	2020	The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.	CD22
30622147	10.1182/bloodadvances.2018026211	2020	Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.	CD22
30736842	10.1186/s13045-019-0703-z	2020	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.	CD22
30763199	10.1200/JOP.18.00271	2020	Acute Lymphoblastic Leukemia in the Older Adult.	CD22
30764841	10.1186/s13045-019-0705-x	2020	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia.	CD22
30807395	10.1097/MPH.0000000000001440	2020	Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.	CD22
30842058	10.1016/S1470-2045(19)30031-2	2020	Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.	CD22
31011424	10.1186/s40364-019-0160-4	2020	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.	CD22
31039409	10.1016/j.bbmt.2019.04.020	2020	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.	CD22
31068044	10.1080/10428194.2019.1608536	2020	Hairy cell leukemia: present and future directions.	CD22
31092071	10.1080/10428194.2019.1605071	2020	Recent advances in the treatment of acute lymphoblastic leukemia.	CD22
31110217	10.1038/s41375-019-0488-7	2020	CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.	CD22
31135529	10.1097/PPO.0000000000000381	2020	Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.	CD22
31307896	10.1016/j.clml.2019.06.011	2020	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.	CD22
31365753		2020	Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults.	CD22
31387880	10.1182/bloodadvances.2019000219	2020	Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.	CD22
31435023	10.1038/s41375-019-0548-z	2020	Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.	CD22
31469898		2020	Pediatric Acute Lymphoblastic Leukemia.	CD22
31522426	10.1007/978-1-4939-9650-6_17	2020	Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia.	CD22
31523577	10.7759/cureus.5150	2020	Recurrence of Gastric Mucosa-associated Lymphoid Tissue Lymphoma in the Pleura: A Case Report.	CD22
31566728	10.1111/bjh.16207	2020	Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.	CD22
31578576	10.3892/or.2019.7335	2020	CAR T cell therapy: A new era for cancer treatment (Review).	CD22
31591741	10.1002/ajh.25653	2020	Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.	CD22
31594764	10.1182/bloodadvances.2019000507	2020	Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.	CD22
31605845	10.1016/j.wneu.2019.09.158	2020	Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.	CD22
31611454	10.4103/IJPM.IJPM_520_18	2020	FLI1 and MIC2 expression in precursor B-lymphoblastic leukemia with Burkitt-like morphology and extensive extramedullary involvement: A diagnostic challenge in pediatric small round cell tumor.	CD22
31643018	10.1007/s11899-019-00544-6	2020	Driving the CAR to the Bone Marrow Transplant Program.	CD22
31697824	10.1182/blood.2019000017	2020	Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.	CD22
31753002	10.1186/s40425-019-0790-y	2020	Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.	CD22
31766014	10.6004/jnccn.2019.5030	2020	Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond.	CD22
31808880	10.1182/hematology.2019000018	2020	Mechanisms of and approaches to overcoming resistance to immunotherapy.	CD22
31869864	10.1111/bjh.16339	2020	Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.	CD22
31894255	10.3892/ijmm.2019.4418	2020	Precision medicine for human cancers with Notch signaling dysregulation (Review).	CD22
31944549	10.1002/pbc.28112	2020	Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.	CD22
31977556	10.1097/CM9.0000000000000638	2020	Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.	CD22
32040482	10.1371/journal.pone.0227586	2020	Expression of the muscle-associated gene MYF6 in hairy cell leukemia.	CD22
32063474	10.1016/j.jcyt.2020.01.008	2020	Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.	CD22
32090132	10.1155/2020/9736159	2020	Upregulation of CD146 in Pediatric B-Cell Acute Lymphocytic Leukemia and Its Implications on Treatment Outcomes.	CD22
32117707	10.3389/fonc.2020.00020	2020	SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human.	CD22
32222815	10.1007/s00432-020-03198-7	2020	Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.	CD22
32232138	10.1021/acscentsci.9b00956	2020	Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy.	CD22
32320280	10.1200/EDBK_278171	2020	Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia.	CD22
32447930	10.3760/cma.j.issn.0253-2727.2020.04.004	2020	[CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].	CD22
32536138	10.3760/cma.j.issn.0253-2727.2020.05.008	2020	[Clinical characteristics and gene expression profiles in children with ETV6-RUNX1 acute lymphoblastic leukemia].	CD22
32589978	10.1016/S2352-3026(20)30144-7	2020	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.	CD22
32624542	10.11406/rinketsu.61.673	2020	[Current status of cancer immunotherapy for relapsed/refractory acute lymphoblastic leukemia in children and adolescents in Japan].	CD22
32774494	10.3892/ol.2020.11882	2020	Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.	CD22
32908056	10.11406/rinketsu.61.922	2020	[Antibody therapy for acute lymphoblastic leukemia].	CD22
32955830	10.23736/S0026-4806.20.07031-7	2020	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.	CD22
33067942	10.19746/j.cnki.issn.1009-2137.2020.05.010	2020	[Comparison of Pathological Immunohistochemical and Flow Immunotyping Results of Patients with Lymphoma Cell Leukemia and Its Clinical Significance].	CD22
33173488	10.1159/000510403	2020	High-Grade Epstein-Barr Virus-Negative Biphenotypic Lymphoma with Expression of B- and T-Cell Markers and Leukemia Presentation: Case Report and Literature Review.	CD22
27598971	10.1002/cyto.b.21482	2019	A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.	CD22
28109040	10.1002/cyto.b.21512	2019	Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.	CD22
28187524	10.1002/cyto.b.21517	2019	Phenotypic Characterization of Trisomy 12 Monoclonal B-Cell Lymphocytosis.	CD22
28616864	10.1111/bjh.14806	2019	A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.	CD22
28677896	10.1111/bjh.14820	2019	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.	CD22
28819740	10.1007/s40265-017-0802-5	2019	Inotuzumab Ozogamicin: First Global Approval.	CD22
28859185	10.1001/jamaoncol.2017.2380	2019	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.	CD22
28888074	10.1002/cyto.b.21591	2019	Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.	CD22
29035453	10.7754/Clin.Lab.2017.170406	2019	Immunophenotyping of Chronic Lymphocytic Leukemia.	CD22
29142069	10.1158/1535-7163.MCT-17-0776	2019	CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models.	CD22
29155426	10.1038/nm.4441	2019	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.	CD22
29220871	10.1002/cyto.b.21605	2019	Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia.	CD22
29352703	10.1016/S1470-2045(18)30011-1	2019	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.	CD22
29508899	10.1002/cncr.31317	2019	Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.	CD22
29883379	10.3390/toxins10050210	2019	Domain II of <i>Pseudomonas</i> Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.	CD22
29931220	10.1001/jamaoncol.2018.1915	2019	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.	CD22
29968492	10.1177/1066896918784669	2019	Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.	CD22
30048343	10.1097/CJI.0000000000000241	2019	Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.	CD22
30058145	10.1002/ajh.25235	2019	Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.	CD22
30087554	10.2147/DDDT.S150317	2019	Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.	CD22
30090971	10.1007/s11523-018-0584-z	2019	Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.	CD22
30120708	10.1007/s11899-018-0470-x	2019	CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.	CD22
30212602	10.1002/cpcy.44	2019	Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies.	CD22
30267011	10.1038/s41375-018-0265-z	2019	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.	CD22
30295242	10.7534/j.issn.1009-2137.2018.05.008	2019	[Relationship between Immune Differentiation Antigen and Minimal Residual Disease in Childhood B-ALL].	CD22
30305504	10.11406/rinketsu.59.2019	2019	[Strategy for treatment of acute lymphoblastic leukemia].	CD22
30357593	10.1007/s40265-018-1000-9	2019	Moxetumomab Pasudotox: First Global Approval.	CD22
30442119	10.1186/s12885-018-5026-x	2019	Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.	CD22
30466749	10.1016/j.beha.2018.09.015	2019	Should immunologic strategies be incorporated into frontline ALL therapy?	CD22
30482769	10.1182/bloodadvances.2018020198	2019	No free rides: management of toxicities of novel immunotherapies in ALL, including financial.	CD22
30504286	10.1182/asheducation-2018.1.9	2019	Antibody-based therapies in patients with acute lymphoblastic leukemia.	CD22
30504288	10.1182/asheducation-2018.1.25	2019	No free rides: management of toxicities of novel immunotherapies in ALL, including financial.	CD22
30583670	10.31557/APJCP.2018.19.12.3463	2019	Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma	CD22
30608452	10.1097/MD.0000000000014018	2019	Multiple myeloma secondary to acute lymphoblastic leukemia: A case report.	CD22
30623490	10.1002/ajh.25394	2019	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.	CD22
30791598	10.3390/toxins11020127	2019	Augmentation of Saporin-Based Immunotoxins for Human Leukaemia and Lymphoma Cells by Triterpenoid Saponins: The Modifying Effects of Small Molecule Pharmacological Agents.	CD22
30995847	10.14735/amko201990	2019	Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.	CD22
31110075	10.1158/1078-0432.CCR-18-3784	2019	Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.	CD22
31187521	10.1002/hon.2594	2019	New treatment options in hairy cell leukemia with focus on BRAF inhibitors.	CD22
31418354	10.19746/j.cnki.issn.1009-2137.2019.04.008	2019	[Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].	CD22
26860883	10.1002/cyto.b.21361	2018	Unilateral uveitis masquerade syndrome caused by diffuse large B-cell lymphoma diagnosed using multiparametric flow cytometry of the aqueous humor.	CD22
27018867	10.1002/cyto.b.21373	2018	CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases.	CD22
27114443	10.1158/1078-0432.CCR-15-2500	2018	Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.	CD22
27154915	10.1158/1078-0432.CCR-15-2488	2018	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.	CD22
27282574	10.1016/j.bcmd.2016.04.004	2018	Flow-cytometry-based evaluation of peripheral blood lymphocytes in prognostication of newly diagnosed DLBCL patients.	CD22
27601593	10.1158/1078-0432.CCR-16-0772	2018	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.	CD22
27689397	10.18632/oncotarget.12247	2018	A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.	CD22
27701909	10.1080/10428194.2016.1235273	2018	Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.	CD22
27784356	10.7534/j.issn.1009-2137.2016.05.013	2018	[Clinicopathologic Characteristics and Outcome of Isolated Ovarian Relapse in Adolescent with Acute Lymphoblastic Leukemia].	CD22
27808110	10.1038/srep36012	2018	Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy.	CD22
27964867	10.1016/S2352-3026(16)30168-5	2018	Consolidation anti-CD22 fractionated radioimmunotherapy with <sup>90</sup>Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.	CD22
28024477	10.7534/j.issn.1009-2137.2016.06.013	2018	[A Retrospective Study of Ph Negative Adolescent and Young Adults with Acute B Lymphoblastic Leukemia in Two Centers].	CD22
28041583	10.1016/S2352-3026(16)30171-5	2018	Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.	CD22
28154086	10.3324/haematol.2016.159905	2018	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.	CD22
28423727	10.18632/oncotarget.16141	2018	Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.	CD22
28515942	10.1186/s40425-017-0246-1	2018	A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.	CD22
28556822	10.3390/toxins9060182	2018	Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.	CD22
28687420	10.1016/S2352-3026(17)30103-5	2018	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.	CD22
28713070	10.4274/tjh.2017.0085	2018	The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.	CD22
28776425	10.2217/fon-2017-0233	2018	Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.	CD22
28821272	10.1186/s13045-017-0516-x	2018	Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.	CD22
28829594	10.1021/jacs.7b03208	2018	CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells.	CD22
29050699	10.1016/j.beha.2017.07.010	2018	How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?	CD22
29075958	10.1007/s11684-017-0558-z	2018	A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation.	CD22
29118234	10.6004/jnccn.2017.7045	2018	Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.	CD22
29316610	10.3390/toxins10010032	2018	Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.	CD22
29323085	10.4103/IJPM.IJPM_379_17	2018	CD19-negative B-lineage acute lymphoblastic leukemia: A diagnostic and therapeutic challenge.	CD22
29432154	10.1073/pnas.1714512115	2018	5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.	CD22
29501750	10.1016/j.yexmp.2018.02.005	2018	Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.	CD22
29517084	10.1358/dot.2017.53.12.2737934	2018	Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.	CD22
29609506	10.1080/13543784.2018.1459560	2018	Ublituximab for the treatment of CD20 positive B-cell malignancies.	CD22
29665916	10.7534/j.issn.1009-2137.2018.02.026	2018	[Characteristics and Diagnostic Values of Bone Marrow Cell Morphology and Immunophenotyping in Lymphoma Cell Leukemia].	CD22
29754509	10.1556/650.2018.31059	2018	[New and traditional directions in the biology and management of childhood acute lymphoblastic leukemia].	CD22
29913470		2018	Inotuzumab ozogamicin (Besponsa)--an antibody-drug conjugate for ALL.	CD22
30066366	10.1111/ijlh.12909	2018	An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping.	CD22
30111389	10.7534/j.issn.1009-2137.2018.04.001	2018	[Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia].	CD22
30113764	10.1111/ijlh.12912	2018	Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio.	CD22
30372691	10.1159/000492941	2018	Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.	CD22
25612555	10.1002/cyto.b.21227	2017	The utility of multiparametric seven-color flow cytometry in the detection of double hit lymphoma in ascitic fluid samples.	CD22
26230248	10.1021/jacs.5b06166	2017	Prosthetic Antigen Receptors.	CD22
26687796	10.1016/S2352-3026(15)00020-4	2017	(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.	CD22
26826117	10.1158/1535-7163.MCT-15-0685	2017	A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells.	CD22
26921100	10.1016/j.imlet.2016.02.014	2017	Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.	CD22
26939705	10.1158/1535-7163.MCT-15-0828	2017	Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.	CD22
27011303	10.1586/17474086.2016.1170593	2017	Immunotherapy approaches to treat adult acute lymphoblastic leukemia.	CD22
27084248	10.1007/s12185-016-1971-9	2017	Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature.	CD22
27101015	10.1007/s11899-016-0326-1	2017	Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.	CD22
27198897	10.1208/s12248-016-9929-7	2017	Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.	CD22
27392242	10.1055/s-0042-110495	2017	Saponins from Saponaria officinalis L. Augment the Efficacy of a Rituximab-Immunotoxin.	CD22
27438018	10.1097/MPH.0000000000000624	2017	Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.	CD22
27475429	10.1007/s11899-016-0336-z	2017	Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.	CD22
27486888	10.1089/gtmb.2016.0006	2017	Screening of Variations in CD22 Gene in Children with B-Precursor Acute Lymphoblastic Leukemia.	CD22
27506529	10.1007/s00262-016-1873-y	2017	The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.	CD22
27521873	10.1016/j.leukres.2016.07.009	2017	New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.	CD22
27524505	10.1016/j.canlet.2016.08.007	2017	Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.	CD22
27559941	10.1097/MD.0000000000004128	2017	Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.	CD22
27607436	10.1159/000448447	2017	Mixed Phenotype Acute Leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and Other Chromosome Abnormalities.	CD22
27820973	10.1080/14728214.2016.1257606	2017	Emerging biological therapies to treat acute lymphoblastic leukemia.	CD22
27825459	10.1016/j.beha.2016.08.024	2017	Origin of Waldenstrom's macroglobulinaemia.	CD22
28009435	10.1111/bph.13697	2017	Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.	CD22
28031181	10.1182/blood-2016-06-722900	2017	Ibrutinib inhibits pre-BCR<sup>+</sup> B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.	CD22
28069570	10.1158/2159-8290.CD-NB2017-001	2017	Anti-CD22 CAR Therapy Leads to ALL Remissions.	CD22
28088906	10.2174/0929867324666170113105733	2017	Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.	CD22
28152223	10.1111/ejh.12862	2017	Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.	CD22
28324281	10.1007/s12185-017-2206-4	2017	Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.	CD22
28449314	10.1002/pbc.26604	2017	Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.	CD22
28533834	10.11604/pamj.2017.26.111.11446	2017	[Splenic marginal zone lymphoma].	CD22
28781269	10.11406/rinketsu.58.749	2017	Chronic lymphocytic leukemia/small lymphocytic lymphoma with t (2;18) (p12;q21) accompanied by a cutaneous nodule with histological features of diffuse large B-cell lymphoma.	CD22
28857075	10.1038/nrclinonc.2017.128	2017	Chimeric antigen receptor T-cell therapies for lymphoma.	CD22
28938559	10.18632/oncotarget.16871	2017	Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance.	CD22
28983018	10.1182/blood-2017-02-749101	2017	Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.	CD22
29110361	10.1002/ajh.24936	2017	Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.	CD22
29155023	10.1016/j.yexmp.2017.11.007	2017	Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.	CD22
23714527	10.14694/EdBook_AM.2013.33.294	2016	Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.	CD22
24952935	10.1016/j.clinthera.2014.05.010	2016	Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells.	CD22
25563425	10.3109/10428194.2014.1001988	2016	Novel therapeutic options for relapsed hairy cell leukemia.	CD22
25669432	10.1038/mt.2015.22	2016	Intracellular delivery system for antibody-Peptide drug conjugates.	CD22
25707288	10.3109/10428194.2015.1017821	2016	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.	CD22
25770294	10.1158/1078-0432.CCR-14-2877	2016	Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.	CD22
25832872	10.2217/fon.15.31	2016	Targeting leukemic stem cells with multifunctional bioactive polypeptide nanoparticles.	CD22
25840969	10.1158/1078-0432.CCR-14-2035	2016	A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.	CD22
25889802	10.1186/s12934-015-0202-z	2016	Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.	CD22
25900401	10.1517/13543784.2015.1038342	2016	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.	CD22
25957418	10.18632/oncotarget.3720	2016	Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.	CD22
26017478	10.12659/MSM.894321	2016	MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis.	CD22
26134015	10.3760/cma.j.issn.0253-2727.2015.06.010	2016	[Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma].	CD22
26194424	10.1007/s11912-015-0466-9	2016	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.	CD22
26277675		2016	Triple cancer: chronic lymphocytic leukemia with bladder and prostate carcinoma.	CD22
26288837	10.1016/j.ebiom.2015.04.016	2016	Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.	CD22
26318093	10.1016/j.critrevonc.2015.08.014	2016	A review of monoclonal antibody therapies in lymphoma.	CD22
26341366	10.1007/s00259-015-3175-6	2016	High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.	CD22
26379425	10.2147/DDDT.S86764	2016	Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem.	CD22
26470977	10.4103/0255-0857.167324	2016	Unusual fungal sepsis of Alternaria alternata in acute lymphoblastic leukaemia in an adult patient.	CD22
26515759	10.1186/s13045-015-0218-1	2016	Establishment and characterization of a novel MYC/BCL2 double-hit diffuse large B cell lymphoma cell line, RC.	CD22
26524013	10.7534/j.issn.1009-2137.2015.05.001	2016	[Analysis of Immunophenotypes in 329 Patients with B-ALL at Different Ages].	CD22
26605343	10.1155/2015/561814	2016	A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.	CD22
26637749	10.1182/asheducation-2015.1.400	2016	The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia.	CD22
26654587	10.1586/14737140.2016.1131614	2016	Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia.	CD22
26683093	10.1002/chem.201503999	2016	Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells.	CD22
26780449	10.2217/imt.15.108	2016	Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.	CD22
26783163	10.1586/17474086.2016.1143771	2016	Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.	CD22
26868143	10.1007/s00428-015-1881-x	2016	CD27-positive hairy cell leukemia-Japanese variant.	CD22
26962787	10.1097/MD.0000000000002904	2016	Burkitt-Type Acute Lymphoblastic Leukemia With Precursor B-Cell Immunophenotype and Partial Tetrasomy of 1q: A Case Report.	CD22
27069035	10.1093/labmed/lmw009	2016	Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall.	CD22
27241147	10.11817/j.issn.1672-7347.2016.04.006	2016	[Pathologic characteristics of bone marrow for CD5 positive small B cell lymphoma].	CD22
27285277	10.1016/j.ijscr.2016.05.041	2016	Marginal zone lymphoma of the breast-A diminished role for surgery.	CD22
27292104	10.1056/NEJMoa1509277	2016	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.	CD22
22453099	10.4161/mabs.4.2.19136	2015	Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.	CD22
23714549	10.14694/EdBook_AM.2013.33.366	2015	Developing novel strategies to target B-cell malignancies.	CD22
23841506	10.3109/10428194.2013.823493	2015	Novel targeted therapies in acute lymphoblastic leukemia.	CD22
24289109	10.3109/10428194.2013.867486	2015	Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.	CD22
24623281	10.1007/s11899-014-0202-9	2015	Novel antibody therapy in acute lymphoblastic leukemia.	CD22
24717996	03.2014/JCPSP.S27S28	2015	Variant hairy cell leukemia following papillary urothelial neoplasm of bladder.	CD22
24739837	10.4103/0377-4929.130904	2015	Your dilemma, my identity: unusual immunogenetic profiles of pediatric B cell acute lymphoblastic leukemia.	CD22
24754692	10.1111/imj.12390	2015	CD5-positive follicular lymphoma: prognostic significance of this aberrant marker?	CD22
24759024	10.3760/cma.j.issn.0253-2727.2014.04.019	2015	[The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders].	CD22
24816427	10.1371/journal.pone.0096697	2015	Generation of anti-idiotype scFv for pharmacokinetic measurement in lymphoma patients treated with chimera anti-CD22 antibody SM03.	CD22
24841238	10.1371/journal.pone.0098315	2015	Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.	CD22
24845957	10.1002/cyto.b.21176	2015	The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?	CD22
24862406	10.1002/anie.201402606	2015	Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions.	CD22
24981395	10.1111/ejh.12408	2015	Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.	CD22
25150258	10.3324/haematol.2014.112110	2015	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.	CD22
25196579	10.1111/bjh.13066	2015	Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.	CD22
25241275	10.1016/j.leukres.2014.08.014	2015	Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.	CD22
25304309	10.1016/j.molimm.2014.09.014	2015	Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.	CD22
25320372	10.1158/1078-0432.CCR-14-0437	2015	Are we nearing an era of chemotherapy-free management of indolent lymphoma?	CD22
25355407	10.1186/s13045-014-0058-4	2015	New antibody approaches to lymphoma therapy.	CD22
25382151	10.1111/bjh.13205	2015	Current status of antibody therapy in ALL.	CD22
25407953	10.1002/ajh.23901	2015	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.	CD22
25427174	10.4161/19420862.2014.985519	2015	Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.	CD22
25440606	10.1053/j.seminoncol.2014.07.004	2015	Radioimmunoconjugates for the treatment of cancer.	CD22
25484043	10.4161/19420862.2014.979081	2015	Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.	CD22
25486958	10.1016/j.clml.2014.04.015	2015	Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.	CD22
25552705	10.3324/haematol.2014.120220	2015	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.	CD22
25567759	10.1039/c4ib00221k	2015	CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.	CD22
25659406	10.1111/bjh.13306	2015	CD22ΔE12 as a molecular target for RNAi therapy.	CD22
25708834	10.1038/leu.2015.48	2015	Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.	CD22
25728039	10.1002/pbc.25410	2015	Characterization of CD22 expression in acute lymphoblastic leukemia.	CD22
25732247	10.1002/pbc.25454	2015	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.	CD22
25775418	10.1517/14712598.2015.1024652	2015	Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.	CD22
25916639		2015	[Pathological diagnosis of pediatric Burkitt lymphoma involving bone marrow].	CD22
25999456	10.1182/blood-2014-08-596403	2015	Monoclonal antibodies in acute lymphoblastic leukemia.	CD22
26064133	10.1155/2015/953297	2015	Disseminated Gastric MALT Lymphoma with Monoclonal Gammopathy, t(11;18)(q21;q21), and Subsequent Development of T-Large Granular Lymphocytic Leukemia: A Case Report and Review of the Literature.	CD22
23075320	10.1021/mp300338s	2014	Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate.	CD22
23313065	10.1016/j.clml.2012.12.003	2014	Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.	CD22
23475897	10.1158/2159-8290.CD-RW2013-014	2014	Anti-CD20 and CD22 therapy is effective in non-Hodgkin lymphoma.	CD22
23598530	10.1158/1535-7163.MCT-12-1173	2014	DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.	CD22
23696252	10.1007/s40259-013-0016-7	2014	Targeting CD22 in B-cell malignancies: current status and clinical outlook.	CD22
23818738		2014	Evaluation of the reactive T-cell infiltrate in uveitis and intraocular lymphoma with flow cytometry of vitreous fluid (an American Ophthalmological Society thesis).	CD22
23927500	10.1111/ejh.12183	2014	BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.	CD22
24000241	10.1002/pbc.24721	2014	Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.	CD22
24061774	10.1007/s12185-013-1432-7	2014	Multiparameter flow cytometry is necessary for detection, characterization and diagnostics of composite mature B-cell lymphoproliferative neoplasms.	CD22
24070652	10.1016/j.leukres.2013.08.005	2014	Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.	CD22
24076579	10.1097/CCO.0000000000000011	2014	Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches.	CD22
24097105	10.1097/CCO.0000000000000009	2014	Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.	CD22
24169826	10.1182/blood-2012-12-473090	2014	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.	CD22
24319203	10.1182/asheducation-2013.1.348	2014	T-cell adoptive immunotherapy for acute lymphoblastic leukemia.	CD22
24389139	10.2741/e688	2014	Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.	CD22
24395821	10.1158/0008-5472.CAN-13-1436	2014	A reevaluation of CD22 expression in human lung cancer.	CD22
24433007	10.3109/1061186X.2013.878942	2014	Targeted liposomal drug delivery systems for the treatment of B cell malignancies.	CD22
24579885	10.1111/bjh.12778	2014	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.	CD22
24652183	10.7705/biomedica.v33i3.1441	2014	[Correlation of the t(9;22), t(12;21), and DNA hyperdiploid content with immunophenotype and proliferative rate of leukemic B-cells of pediatric patients with B-cell acute lymphoblastic leukemia].	CD22
24763004	10.7534/j.issn.1009-2137.2014.02.016	2014	[Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry].	CD22
24876818	10.5114/wo.2013.38570	2014	Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.	CD22
25214564	10.1093/jnci/dju307	2014	Marshaling the immune system to eliminate minimal residual disease in B-ALL.	CD22
22064604	10.2310/JIM.0b013e31823908f9	2013	CD200 expression in B-cell chronic lymphoproliferative disorders.	CD22
22170090	10.1007/s12032-011-0136-1	2013	Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.	CD22
22448921	10.3109/10428194.2012.679267	2013	Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.	CD22
22520947	10.1016/j.humpath.2012.01.003	2013	Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation.	CD22
22749831	10.1016/j.jaut.2012.05.014	2013	B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.	CD22
22777817	10.1002/eji.201242574	2013	Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.	CD22
22839105	10.1021/pr300079c	2013	Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity.	CD22
22965838	10.1002/eji.201242629	2013	Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model.	CD22
23040543	10.1016/j.leukres.2012.09.010	2013	Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.	CD22
23072775		2013	Antibody-drug conjugate technology development for hematologic disorders.	CD22
23116517	10.1021/bc300488f	2013	Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.	CD22
23143625	10.1002/jcla.21540	2013	Flow cytometry immunophenotyping evaluation in acute lymphoblastic leukemia: correlation to factors affecting clinic outcome.	CD22
23236148	10.1073/pnas.1214638110	2013	Production of unique immunotoxin cancer therapeutics in algal chloroplasts.	CD22
23243285	10.1182/blood-2012-06-438002	2013	Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.	CD22
23282005	10.1186/1756-6614-6-1	2013	Case report: rare case of infiltration of small lymphocytic B-cell lymphoma in the thyroid gland of female patient with B-cell chronic lymphocytic leukemia (CLL-B/SLL-B).	CD22
23285191	10.1371/journal.pone.0052811	2013	VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.	CD22
23295790	10.1200/JCO.2012.42.7211	2013	Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.	CD22
23347903	10.1016/j.leukres.2012.11.021	2013	Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.	CD22
23355206	10.1309/AJCP0YGM8BLFYHJY	2013	Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.	CD22
23396434	10.1684/abc.2012.0782	2013	[Mantle cell lymphoma diagnosis].	CD22
23411729	10.1182/blood-2012-12-474239	2013	CAReful epitope selection matters.	CD22
23440868	10.1002/anie.201207267	2013	C-4 modified sialosides enhance binding to Siglec-2 (CD22): towards potent Siglec inhibitors for immunoglycotherapy.	CD22
23486472	10.1074/jbc.M113.461343	2013	A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.	CD22
23543122	10.7860/JCDR/2013/5169.2768	2013	A hairy cell leukaemia variant - a rare case report.	CD22
23610978		2013	Difficulty in classifying a B cell chronic lymphoproliferative disorder CD5+.	CD22
23628018	10.7534/j.issn.1009-2137.2013.02.006	2013	[Characteristics of 4 specific target antigens in adult acute lymphoblastic leukemia].	CD22
23628035	10.7534/j.issn.1009-2137.2013.02.023	2013	[Immunophenotype analysis of leukemic mantle cell lymphoma].	CD22
23633004	10.1002/cncr.28136	2013	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.	CD22
23633448	10.1002/cncr.28135	2013	CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia.	CD22
23774652	10.1159/000347165	2013	Precursor B-cell lymphoblastic leukemia with surface immunoglobulin light chain expression in 2 chinese patients.	CD22
23821660	10.1182/blood-2012-12-473744	2013	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.	CD22
23875170	10.3389/fonc.2013.00177	2013	Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma.	CD22
23880011	10.1186/1750-9378-8-28	2013	Epstein Barr virus DNA analysis in blood predicts disease progression in a rare case of plasmablastic lymphoma with effusion.	CD22
23922187	10.1002/cncr.28299	2013	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.	CD22
23928529	10.3760/cma.j.issn.0529-5807.2013.04.005	2013	[Clinicopathologic features and differential diagnosis of splenic B-cell marginal zone lymphoma involving bone marrow].	CD22
23998067	10.7860/JCDR/2013/5088.3130	2013	Chronic lymphoproliferative disorders at an Indian tertiary cancer centre - the panel sufficiency in the diagnosis of chronic lymphocytic leukaemia.	CD22
24145652	10.1097/PAS.0000000000000091	2013	CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: diagnostic and prognostic impact.	CD22
24159161	10.1182/blood-2013-07-514083	2013	Gnawing at Metchnikoff's paradigm.	CD22
21629223	10.1038/mt.2011.104	2012	Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells.	CD22
21756025	10.3109/10428194.2011.604755	2012	Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.	CD22
21800074	10.1007/s12185-011-0900-1	2012	Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.	CD22
21856552	10.3816/CLML.2011.n.040	2012	Post-treatment bone marrow residual disease &gt; 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.	CD22
21869836	10.1038/leu.2011.206	2012	The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.	CD22
21897067		2012	[Novel monoclonal antibodies for the treatment of malignant lymphomas].	CD22
21958552	10.1016/j.blre.2011.08.001	2012	Chemoimmunotherapy in acute lymphoblastic leukemia.	CD22
22003067	10.1158/1078-0432.CCR-11-0487	2012	Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.	CD22
22003069	10.1158/1078-0432.CCR-11-0486	2012	Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.	CD22
22017452	10.1111/j.1365-2141.2011.08901.x	2012	CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.	CD22
22039078	10.1158/1535-7163.MCT-11-0632	2012	Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.	CD22
22048691	10.4161/mabs.3.5.17228	2012	The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.	CD22
22070056		2012	CD22 as a target for cancer therapy.	CD22
22101015	10.1093/protein/gzr053	2012	A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.	CD22
22128838	10.1186/1756-8722-4-49	2012	The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.	CD22
22160041	10.1182/asheducation-2011.1.243	2012	Novel antibody-based therapies for acute lymphoblastic leukemia.	CD22
22180432	10.3324/haematol.2011.049155	2012	The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.	CD22
22230415	10.1177/039463201102400427	2012	Aggressive large B-cell lymphoma in a systemic lupus erythematosus patient with chronic active Epstein-Barr virus infection: a case report.	CD22
22327430	10.4161/mabs.4.1.18348	2012	Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.	CD22
22335424	10.1111/j.1349-7006.2012.02241.x	2012	Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.	CD22
22357139	10.1016/S1470-2045(12)70010-4	2012	Anti-CD22 therapy in acute lymphoblastic leukaemia.	CD22
22357140	10.1016/S1470-2045(11)70386-2	2012	Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.	CD22
22422550	10.1007/s11899-012-0120-7	2012	Antibody therapy for acute lymphoblastic leukemia.	CD22
22467604	10.1002/cyto.b.21017	2012	Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.	CD22
22483155	10.2174/156800912800673211	2012	Novel and emerging drugs for rarer chronic lymphoid leukaemias.	CD22
22500551	10.1517/13543784.2012.679359	2012	Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.	CD22
22507779	10.1179/102453312X13336169155538	2012	Monoclonal antibodies in adult acute lymphoblastic leukemia.	CD22
22509046	10.1073/pnas.1204523109	2012	Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.	CD22
22567217	10.4081/hr.2012.e3	2012	Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry.	CD22
22658480	10.1016/j.prp.2012.04.007	2012	Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukemia: case report and review of literature.	CD22
22706486		2012	Inotuzumab: the most active single agent in acute lymphoblastic leukemia?	CD22
22758202	10.1111/j.1365-2141.2012.09209.x	2012	Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.	CD22
23061343		2012	Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies.	CD22
21123968	10.3960/jslrt.50.107	2011	Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases.	CD22
21178016	10.4049/jimmunol.1003005	2011	CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.	CD22
21198735	10.1111/j.1939-165X.2010.00252.x	2011	Exclusion of cytoplasmic fragments in flow cytometric analysis of lymph node samples from dogs with lymphoma using membrane-permeable violet laser-excitable DNA-binding fluorescent dye (DyeCycle Violet).	CD22
21219397	10.1111/j.1365-2125.2010.03767.x	2011	Treatment of systemic lupus erythematosus with epratuzumab.	CD22
21272942	10.1016/j.vetimm.2010.12.010	2011	Establishment of a novel feline leukemia virus (FeLV)-negative B-cell cell line from a cat with B-cell lymphoma.	CD22
21273093	10.1016/j.critrevonc.2010.12.003	2011	Lymphoblastic lymphoma.	CD22
21347809	10.1007/s00262-011-0978-6	2011	The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.	CD22
21348573	10.3109/10428194.2011.559668	2011	Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.	CD22
21405019	10.1021/bc100579d	2011	Supramolecular complexing of membane Siglec CD22 mediated by a polyvalent heterobifunctional ligand that templates on IgM.	CD22
21454219	10.3816/CLML.2011.n.035	2011	Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM).	CD22
21463109	10.3109/10428194.2011.568651	2011	Tumor markers in hairy cell leukemia.	CD22
21463128	10.3109/10428194.2011.562575	2011	Response of hairy cell leukemia to bendamustine.	CD22
21504287	10.3109/10428194.2011.573039	2011	Immunotoxins with decreased immunogenicity and improved activity.	CD22
21504292	10.3109/10428194.2011.570820	2011	Diagnosis of hairy cell leukemia by flow cytometry.	CD22
21599606	10.3109/10428194.2011.566392	2011	Management of hairy cell leukemia variant.	CD22
21599608	10.3109/10428194.2011.569961	2011	Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.	CD22
21599609	10.3109/10428194.2011.565843	2011	Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.	CD22
21626771	10.2298/sarh1104229c	2011	[Progression of nodal marginal zone lymphoma into diffuse large B cell lymphoma in a patient with Sjögren's syndrome].	CD22
21658624	10.1016/j.beha.2011.03.005	2011	Radioimmunotherapy in follicular lymphoma.	CD22
21666843	10.1007/s12672-010-0045-3	2011	Luteinizing hormone receptor deficiency increases the susceptibility to alkylating agent-induced lymphomagenesis in mice.	CD22
21673350	10.1182/blood-2011-02-336990	2011	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.	CD22
21732928	10.1111/j.1365-2141.2011.08762.x	2011	A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.	CD22
21777289	10.1111/j.1939-1676.2011.0756.x	2011	A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma.	CD22
19150402	10.1016/j.cellsig.2008.12.006	2009	SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux.	CD22
10228003		1999	CD45 regulates tyrosine phosphorylation of CD22 and its association with the protein tyrosine phosphatase SHP-1.	CD22
8475064	10.1073/pnas.90.8.3236	1993	CD22 associates with the human surface IgM-B-cell antigen receptor complex.	CD22
